119th Congress · introduced in the Senate · Jul 23, 2026
Harley Jacobsen Clinical Trial Participant Income Exemption Act of 2026
Official title from Congress.gov
Latest action (Jul 23, 2026): Read twice and referred to the Committee on Finance.
View on Congress.govPolicy area: Taxation
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
6 citations.
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$1,790,000
Spent on own lobbying
…reducing barriers to enrollment including support for and remote access to trials. Harley Jacobson Clinical Trial Participant Income Exemption Act, H.R. 4184, S.5127. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants.
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Taxation/Internal Revenue Code
$1,790,000
Spent on own lobbying
…to enrollment including support for ancillary (non-medical) costs and remote access to trials. Harley Jacobsen Clinical Trial Participant Income Exemption Act, S.5127, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. To amend t…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medical/Disease Research/Clinical Labs
$1,790,000
Spent on own lobbying
…ipate by reducing barriers to enrollment, including support for ancillary (non-medical) costs. Harley Jacobsen Clinical Trial Participant Income Exemption Act, S.5127, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. To amend t…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MURAL HEALTH · lobbying firm or registrant: TROUTMAN STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Medical/Disease Research/Clinical Labs
$50,000
Paid to lobbying firm
Issues related to taxing payments and reimbursements to participants in clinical trials. H. R. 4184/S.5127 To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MURAL HEALTH · lobbying firm or registrant: TROUTMAN STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$50,000
Paid to lobbying firm
Issues related to taxing payments and reimbursements to participants in clinical trials. H. R. 4184/S.5127 To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MURAL HEALTH · lobbying firm or registrant: TROUTMAN STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Taxation/Internal Revenue Code
$50,000
Paid to lobbying firm
Issues related to taxing payments and reimbursements to participants in clinical trials. H. R. 4184/S.5127 To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing